All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Visual abstract | A retrospective study of IL-17 vs IL-23 inhibitors in erythrodermic and pustular psoriasis

Apr 25, 2023
Learning objective: After reading this article, learners will be able to describe the efficacy of IL-17 and IL-23 inhibitors in patients with pustular and erythrodermic psoriasis.

Bookmark this article

The Psoriasis and Psoriatic Arthritis Hub is pleased to present a visual abstract representing data from a multicenter, retrospective study that investigated the efficacy and safety of IL-17 and IL-23 inhibitors in erythrodermic psoriasis (EP) and pustular psoriasis (PP). Currently, data are lacking on the use of IL-17 and IL-23 inhibitors in these rarer forms of psoriasis, although there is evidence that IL-17 inhibitors can effectively treat both EP and PP.1

For this study, data were obtained between 2019 and 2022 from two Italian referral centers (the Dermatology Clinic at the Turin University Hospital and the Dermatology Unit at Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan), with a total of 86 patients included.1 27 patients had EP and 59 had PP. Baseline patient characteristics were similar across disease type and treatment groups, with the exception of higher Psoriasis Area and Severity Index scores (median, 15.0; interquartile range [IQR], 10.0–19.0 vs median, 8.2; IQR, 6.0–13.5; p = 0.009) and a lower incidence of psoriatic arthritis (51% vs 81%; p = 0.043) in patients with PP who received IL-17 inhibitors compared with those who received IL-23 inhibitors.1 It is assumed that some EP patients may have received both IL-17 and IL-23 inhibitors at the same time, due to the baseline patient characteristics data given.

The authors noted several limitations of this study, including the lack of efficacy data for the first 12 weeks after treatment, which is common in retrospective studies, and the small sample size. Both IL-17 and IL-23 inhibitors were effective in treating EP and PP; however, further research is needed to fully elucidate there efficacy in this patient population.

  1. Avallone G, Maronese CA, Murgia G, et al. Interleukin-17 vs. interleukin-23 inhibitors in pustular and erythrodermic psoriasis: a retrospective, multicentre cohort study. J Clin Med. 2023;12(4):1662. DOI: 3390/jcm12041662


Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox